Photodynamic therapy for cancer

Nature Reviews Cancer

Volumn 3, Issue 5, 2003, Pages 380-387

  Dolmans, Dennis E J G J ^a   Fukumura, Dai ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; ANTINEOPLASTIC AGENT; PHOTOFRIN; PHOTOSENSITIZING AGENT; TEMOPORFIN; UNCLASSIFIED DRUG;

BRAIN CANCER; BREAST CANCER; HEAD CANCER; LIGHT; LUNG CANCER; NECK CANCER; PANCREAS CANCER; PHOTOCHEMOTHERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKIN CANCER; HUMAN; IMMUNOLOGY; NEOPLASM; VASCULARIZATION;

HUMANS; NEOPLASMS; PHOTOCHEMOTHERAPY;

EID: 0037711396     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1071     Document Type: Review

References (128)

1. Daniell, M. D. & Hill, J. S. A history of photodynamic therapy. Aust. NZ J. Surg. 61, 340-348 (1991).
2. Ackroyd, R., Kelty, C., Brown, N. & Reed, M. The history of photodetection and photodynamic therapy. Photochem. Photobiol. 74, 656-669 (2001).
3. Spikes, J. D. in Primary Photoprocesses in Biology and Medicine (eds Berghausen, R. V., Jori, G., Land, E. J. & Truscott, T. H.) 209-227 (Plenum Press, New York, 1985).
4. Finsen, N. R. Phototherapy (Edward Arnold, London, 1901).
5. Raab, O. Uber die Wirkung fluoreszierender Stoffe auf Infusorien. Zeitung Biol. 39, 524-526 (1900).
6. Prime, J. Les accidents toxiques par l'eosinate de sodium (Jouve and Boyer, Paris, 1900).
7. von Tappeiner, H. & Jesionek, A. Therapeutische versuche mit fluoreszierenden stoffen. Muench Med. Wochenschr 47, 2042-2044 (1903).
8. von Tappeiner, H. & Jodlbauer, A. Die sensiblilisierende Wirkung fluoreszierender Substanzer Gesammte Untersuchungen uber die photodynamische Erscheinerung (Voger, F. C., Leipzig, 1907).
9. Epstein, J. H. Phototoxicity and photoallergy. Semin. Cutan. Med. Surg. 18, 274-284 (1999).
10. Epstein, J. H. Phototherapy and photochemotherapy. N. Engl. J. Med. 322, 1149-1151 (1990).
11. Hausmann, W. Die sensiblisierende Wirkung des Hematoporphyrins. Biochem. Zeitung 30, 276-316 (1911).
12. Meyer-Betz, F. Untersuchungen uber die biologische photodynamische Wirkung des Hematoporphyrins und anderer Derivative des Blut und Galenafarbstoffs. Dtsch Arch. Klin. 112, 476-503 (1913).
13. Lipson, R. L. & Baldes, E. J. The photodynamic properties of a particular hematoporphyrin derivative. Arch. Dermatol. 82, 508-516 (1960).
14. Lipson, R. L., Baldes, E. J. & Olsen, A. M. The use of an derivative of hematoporphyrin in tumor detection. J. Natl Cancer Inst. 29, 1-11 (1961).
15. Schwartz, S. K., Abolon, K. & Vermund, H. Some relationships of porphyrins, X-rays and tumors. Univ. Minn. Med. Bull. 27, 7-8 (1955).
16. Lipson, R. L., Baldes, E. J. & Olsen, A. M. Hematoporphyrin derivative: a new aid for endoscopic detection of malignant disease. J. Thorac. Cardiovasc. Surg. 42, 623-629 (1961).
17. Dougherty, T. et al. Photodynamic therapy. JNCI Cancer Spectrum 90, 889-905 (1998).
18. Hasan, T., Ortel, B., Moor, A. & Pogue, B. in Holland-Frei Cancer Medicine (eds Kufe, D. et al.) Ch. 40 (BC Decker, Inc., Hamilton, Ontario, 2003).
19. Diamond, I. et al. Photodynamic therapy of malignant tumours. Lancet 2, 1175-1177 (1972).
20. Dougherty, T. J., Grindey, G. B., Fiel, R., Weishaupt, K. R. & Boyle, D. G. Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J. Natl Cancer Inst. 55, 115-121 (1975).
21. Kelly, J. F., Snell, M. E. & Berenbaum, M. C. Photodynamic destruction of human bladder carcinoma. Br. J. Cancer 31, 237-244 (1975).
22. Kelly, J. F. & Snell, M. E. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J. Urol. 115, 150-151 (1976).
23. Dougherty, T. J. et al. Photoradiation therapy for the treatment of malignant tumors, Cancer Res. 38, 2526-2635 (1978).
24. Hayata, Y., Kato, H., Konaka, C., Ono, J. & Takizawa, N. Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer. Chest 81, 269-277 (1982).
25. McCaughan, J. S. Jr, Hicks, W., Laufman, L., May, E. & Roach, R. Palliation of esophageal malignancy with photoradiation therapy. Cancer 54, 2905-2910 (1984).
26. Balchum, O. J., Doiron, D. R. & Huth, G. C. Photoradiation therapy of endobronchial lung cancers employing the photodynamic action of hematoporphyrin derivative. Lasers Surg. Med. 4, 13-30 (1984).
27. Hayata, Y., Kato, H., Okitsu, H., Kawaguchi, M. & Konaka, C. Photodynamic therapy with hematoporphyrin derivative in cancer of the upper gastrointestinal tract. Semin. Surg. Oncol. 1, 1-11 (1985).
28. Dougherty, T. J. et al. Photoradiation in the treatment of recurrent breast carcinoma. J. Natl Cancer Inst. 62, 231-237 (1979).
29. Mang, T. S., Allison, R., Hewson, G., Snyder, W. & Moskowitz, R. A Phase II/III study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J. Sci. Am. 4, 378-384 (1998).
30. Dimofte, A., Zhu, T. C., Hahn, S. M. & Lustig, R. A. In vivo light dosimetry for motexafin lutetium-mediated PDT of breast cancer. Lasers Surg. Med. 31, 305-312 (2002).
31. Ward, B. G., Forbes, I. J., Cowled, P. A., McEvoy, M. M. & Cox, L. W. The treatment of vaginal recurrences of gynecologic malignancy with phototherapy following hematoporphyrin derivative pretreatment. Am. J. Obstet. Gynecol. 142, 356-357 (1982).
32. Hornung, R. Photomedical approaches for the diagnosis and treatment of gynecologic cancers. Curr. Drug Targets Immune Endocr. Metabol. Disord. 1, 165-177 (2001).
33. Fehr, M. K. et al Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevulinic acid. Gynecol. Oncol. 84, 62-66 (2002).
34. Gomer, C. J., Doiron, D. R., Jester, J. V., Szirth, B. C. & Murphree, A. L. Hematoporphyrin derivative photoradiation therapy for the treatment of intraocular tumors: examination of acute normal ocular tissue toxicity. Cancer Res. 43, 721-727 (1983).
35. Favilla, I. et al. Photodynamic therapy: a 5 year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture. Melanoma Res. 5, 355-364 (1995).
36. Landau, I. M., Steen, B. & Seregard, S. Photodynamic therapy for circumscribed choroidal haemangioma. Acta Ophthalmol. Scand. 80, 531-536 (2002).
37. Sandeman, D. R. Photodynamic therapy in the management of malignant gliomas: a review. Lasers Med. Sci. 1, 163-167 (1986).
38. Hill, J. S. et al. Selective uptake of hematoporphyrin derivative into human cerebral glioma. Neurosurgery 26, 248-254 (1990).
39. Popovic, E. A., Kaye, A. H. & Hill, J. S. Photodynamic therapy of brain tumors. J. Clin. Laser Med. Surg. 14, 251-261 (1996).
40. Rosenthal, M. A. et al. Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin. J. Clin. Oncol. 19, 519-524 (2001).
41. Schweitzer, V. G. Photodynamic therapy for treatment of head and neck cancer. Otolaryngol. Head Neck Surg. 102, 225-232 (1990).
42. Biel, M. A. Photodynamic therapy and the treatment of head and neck neoplasia. Laryngoscope 108, 1259-1268 (1998).
43. Barr, H., Krasner, N., Boulos, P. B., Chatlani, P. & Bown, S. G. Photodynamic therapy for colorectal cancer: a quantitative pilot study. Br. J. Surg. 77, 93-96 (1990).
44. Mlkvy, P. et al. Photodynamic therapy for gastrointestinal tumors using three photosensitizers - ALA induced PPIX, Photofrin and MTHPC. A pilot study. Neoplasma 45, 157-161 (1998).
45. Allison, R. R., Mang, T. S. & Wilson, B. D. Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies. Semin. Cutan. Med. Surg. 17, 153-163 (1998).
46. Taber, S. W., Fingar, V. H., Coots, C. T. & Wieman, T. J. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study. Clin. Cancer Res. 4, 2741-2746 (1998).
47. DeLaney, T. F. et al. Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int. J. Radiat. Oncol. Biol. Phys. 25, 445-457 (1993).
48. Pass, H. I. et al. Intrapleural photodynamic therapy: results of a phase I trial. Ann. Surg. Oncol. 1, 28-37 (1994).
49. Ortner, M. A. et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 114, 536-542 (1998).
50. Bown, S. G. et al. Photodynamic therapy for cancer of the pancreas. Gut 50, 549-557 (2002).
51. McBride, G. Studies expand potential uses of photodynamic therapy. JNCI Cancer Spectrum 94, 1740-1742 (2002).
52. Henderson, B. W. & Dougherty, T. J. How does photodynamic therapy work? Photochem. Photobiol. 55. 145-157 (1992).
53. Gomer, C. J. & Razum, N. J. Acute skin response in albino mice following porphyrin photosensitization under oxic and anoxic conditions. Photochem. Photobiol. 40, 435-439 (1984).
54. Moan, J. & Berg, K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem. Photobiol. 53, 549-553 (1991).
55. Henderson, B. W. et al. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res. 45. 572-576 (1985).
56. Korbelik, M. & Krosl, G. Cellular levels of photosensitisers in tumours: the role of proximity to the blood supply. Br. J. Cancer 70, 604-610 (1994).
57. Tromberg, B. J. et al. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem. Photobiol. 52, 376-385 (1990).
58. Pogue, B. W., Braun, R. D., Lanzen, J. L., Erickson, C. & Dewhirst, M. W. Analysis of the heterogeneity of pO2 dynamics during photodynamic therapy with verteporfin. Photochem. Photobiol. 74, 700-706 (2001).
59. Pogue, B. W. et al. Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. Cancer Res. 63, 1026-1033 (2003).
60. Messmann, H. et al. Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. Br. J. Cancer 72, 589-594 (1995).
61. Pogue, B. W. & Hasan, T. A theoretical study of light fractionation and dose-rate effects in photodynamic therapy. Radiat. Res. 147, 551-559 (1997).
62. Iinuma, S. et al In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model, Cancer Res. 59, 6164-6170 (1999).
63. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases: from genes to function to therapy. Nature 407, 249-257 (2000).
64. Jain, R. K. & Carmeliet, P. F. Vessels of death or life. Sci. Am. 285, 38-45 (2001).
65. Star, W. M. et al. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res. 46, 2532-2540 (1986).
66. Fingar, V. H., Wieman, T. J. & Haydon, P. S. The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using photofrin. Photochem. Photobiol. 66, 513-517 (1997).
67. Fingar, V. H. et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br. J. Cancer 79, 1702-1708 (1999).
68. Dolmans, D. E. et al. Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy Cancer Res. 62, 2151-2156 (2002).
69. Henderson, B. W. & Fingar, V. H. Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res. 47, 3110-3114 (1987).
70. Chen, Q., Chen, H. & Hetzel, F. W. Tumor oxygenation changes post-photodynamic therapy. Photochem. Photobiol. 63, 128-131 (1996).
71. Busch, T. M. et al. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. Cancer Res. 62, 7273-7279 (2002).
72. Henderson, B. W. & Fingar, V. H. Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model. Photochem. Photobiol. 49, 299-304 (1989).
73. Ferrario, A. et al. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 60, 4066-4069 (2000).
74. Ferrario, A., von Tiehl, K., Wong, S., Luna, M. & Gomer, C. J. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 62, 3956-3961 (2002).
75. Reference deleted in proof.
76. Shumaker, B. P. & Hetzel, F. W. Clinical laser photodynamic therapy in the treatment of bladder carcinoma. Photochem. Photobiol. 46, 899-901 (1987).
77. Gollnick, S. O., Liu, X., Owczarczak, B., Musser, D. A. & Henderson, B. W. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res. 57, 3904-3909 (1997).
78. de Vree, W. J. et al. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res. 56, 2908-2911 (1996).
79. Korbelik, M., Krosl, G., Krosl, J. & Dougherty, G. J. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res. 56, 5647-5652 (1996).
80. Korbelik, M. & Dougherty, G. J. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 59, 1941-1946 (1999).
81. Gollnick, S. O., Vaughan, L. & Henderson, B. W. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res. 62, 1604-1608 (2002).
82. Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46, 149-168 (2001).
83. Jain, R. K. The next frontier of molecular medicine: delivery of therapeutics. Nature Med. 4, 655-657 (1998).
84. Dolmans, D. E. et al. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res. 62, 4289-4294 (2002).
85. Dougherty, T. J. An update on photodynamic therapy applications. J. Clin. Laser Med. Surg. 20, 3-7 (2002).
86. Cramers, P. et al. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br. J. Cancer 88, 283-290 (2003).
87. Ruoslahti, E. Specialization of tumour vasculature. Nature Rev. Cancer 2, 83-90 (2002).
88. Peng, Q., Moan, J. & Nesland, J. M. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct. Pathol. 20, 109-129 (1996).
89. Bachor, R., Shea, C., Gillies, R. & Hasan, T. Photosensitized destruction of human bladder carcinoma cells treated with chlorin e6-conjugated microspheres. Proc. Natl Acad. Sci. USA 88, 1580-1584 (1991).
90. Duska, L. R., Hamblin, M. R., Miller, J. L. & Hasan, T. Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. JNCI Cancer Spectrum 91, 1557-1563 (1999).
91. Dougherty, T. J. Hematoporphyrin as a photosensitizer of tumors. Photochem. Photobiol. 38, 377-379 (1983).
92. Dougherty, T. J., Potter, W. R. & Weishaupt, K. R. The structure of the active component of hematoporphyrin derivative. Prog. Clin. Biol. Res. 170, 301-314 (1984).
93. Orenstein, A. et al. A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model. Br. J. Cancer 73, 937-944 (1996).
94. Sibata, C. H., Colussi, V. C., Oleinick, N. L. & Kinsella, T. J. Photodynamic therapy in oncology. Expert Opin. Pharmacother. 2, 917-927 (2001).
95. Ris, H. B. et al. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br. J. Cancer 64, 1116-1120 (1991).
96. Grosjean, P., Savary, J. & Wagnieres, G. Tetra (m-hyrophenyl) chlorin clinical photodynamic therapy of early bronchial and esophageal cancers. Lasers Med. Sci. 8, 236-243 (1993).
97. Rassmussan-Taxdal, D. S., Ward, G. E. & Figge, F. H. Fluorescence of human lymphatic and cancer tissues following high doses of intravenous hematoporphyrin. Cancer 8, 78-81 (1955).
98. Braichotte, D. R., Wagnieres, G. A., Bays, R., Monnier, P. & van den Bergh, H. E. Clinical pharmacokinetic studies of photofrin by fluorescence spectroscopy in the oral cavity, the esophagus, and the bronchi. Cancer 75, 2758-2778 (1995).
99. Kennedy, J. C., Pottier, R. H. & Pross, D. C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J. Photochem. Photobiol. B 6, 143-148 (1990).
100. Kennedy, J. C., Marcus, S. L. & Pottier, R. H. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevutinic acid (ALA); mechanisms and clinical results. J. Clin. Laser Med Surg. 14, 289-304 (1996).
101. Peng, Q. et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 79, 2282-2308 (1997).
102. Stummer, W. et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J. Neurosurg. 93, 1003-1013 (2000).
103. Schmidt-Erfurth, U. & Hasan, T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv. Ophthalmol. 45, 195-214 (2000).
104. Endlicher, E. et al. Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitisation. Gut 46, 314-319 (2001).
105. Berg, K. et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res. 59, 1180-1183 (1999).
106. Mittra, R. A. & Singerman, L. J. Recent advances in the management of age-related macular degeneration. Optom. Vis. Sci. 79, 218-224 (2002).
107. Photodynamic therapy with verteporfin for age-related macular degeneration. American Academy of Ophthalmology. Ophthalmology 107, 2314-2317 (2000).
108. Ortu, P., LaMuraglia, G. M., Roberts, W. G., Flotte, T. J. & Hasan, T. Photodynamic therapy of arteries. A novel approach for treatment of experimental intimal hyperplasia. Circulation 85, 1189-1196 (1992).
109. Chou, T. M. et al. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium. Catheter Cardiovasc. Interv. 57, 387-394 (2002).
110. Szeimies, R. M., Landthaler, M. & Karrer, S. Non-oncologic indications for ALA-PDT. J. Dermatolog. Treat. 13 (Suppl. 1), S13-S18 (2002).
111. Leman, J. A. & Morton, C. A. Photodynamic therapy: applications in dermatology. Expert Opin. Biol. Ther. 2, 45-53 (2002).
112. Trauner K. B. et al. Photodynamic synovectomy using benzoporphyrin derivative in an antigen-induced arthritis model for rheumatoid arthritis. Photochem. Photobiol. 67, 133-139 (1998).
113. Soukos, N. S., Ximenez-Fyvie, L. A., Hamblin, M. R., Socranski, S. S. & Hasan, T. Targeted antimicrobial photochemotherapy. Antimicrob. Agents Chemother. 42, 2595-2601 (1998).
114. Hamblin, M. R., Zahra, T., Contag, C. H., McManus, A. T. & Hasan, T. Optical monitoring and treatment of potentially lethal wound infections in vivo. J. Infect. Dis. (in the press).
115. Hamblin, M. R., Miller, J. L. & Hasan, T. Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res. 56, 5205-5210 (1996).
116. Birchler, M., Viti, F., Zardi, L., Spiess, B. & Neri, D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nature Biotechnol. 17, 984-988 (1999).
117. Friedrich, S. W. et al. Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia 4, 449-463 (2002).
118. de Bruijn, H. S., van der Veen, N., Robinson, D. J. & Star, W. M. Improvement of systemic 5-aminolevulinic acid-based photodynamic therapy in vivo using light fractionation with a 75-minute interval. Cancer Res. 59, 901-904 (1999).
119. Mew, D., Wat, C. K., Towers, G. H. & Levy, J. G. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J. Immunol. 130, 1473-1477 (1983).
120. Goff, B. A., Bamberg, M. & Hasan, T. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res. 51, 4762-4767 (1991).
121. Vrouenraets, M. B. et al. Development of metatetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy. Cancer Res. 59, 1505-1513 (1999).
122. Allison, B. A., Pritchard, P. H. & Levy, J. G. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br. J. Cancer 69, 833-839 (1994).
123. Konan, Y. N., Gurny, R. & Allemann, E. State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B 66, 89-106 (2002).
124. Polo, L., Valduga, G., Jori, G. & Reddi, E. Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts. Int. J. Biochem. Cell Biol. 34, 10-23 (2002).
125. Dougherty, T. J. et al. The role of the peripheral benzodiazepine receptor in photodynamic activity of certain pyropheophorbide ether photosensitizers: albumin site II as a surrogate marker for activity. Photochem. Photobiol. 76, 91-97 (2002).
126. Swamy, N., James, D. A., Mohr, S. C., Hanson, R. N. & Ray, R. An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cells. Bioorg. Med. Chem. 10, 3237-3243 (2002).
127. Zhou, C. N., Milanesi, C. & Jori, G. An ultrastructural comparative evaluation of tumors photosensitized by porphyrins administered in aqueous solution, bound to liposomes or to lipoproteins. Photochem. Photobiol. 48, 487-492 (1988).
128. Richter, A. M. et al. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem. Photobiol. 57, 1000-1006 (1993).